Track medtech innovations from your desktop, subscribe to Innovation Hub.

Learn More

Global Opportunities in Neurostimulation Technologies Targeting Neurological Conditions

114 Pages | 33 Exhibits | Forecasts Through 2024
market-report-samples/GlobalMarketSegments2.jpg market-report-samples/GlobalMarketSegments3caps.jpg market-report-samples/GlobalMarketSegmentsCaps.jpg
Buy Now

Overview

Global sales of neurostimulation technologies targeting neurological disorders were estimated at more than $1.5 billion in 2019. Among these, deep brain stimulation (DBS) for Parkinson's and Essential Tremor contribute the largest share of sales (56%) based on the relatively established nature of this application and the high cost of the implants.  It is followed by DRE (29% of sales), which is also dominated by expensive implants.  In contrast, neurostimulation-based treatment of MDD and post-stroke extremity motor dysfunction are served primarily by noninvasive technologies. The former is a more recent application that is expected to continue its reliance on noninvasive technologies, whereas the latter is a more traditional user of noninvasive technologies that may be augmented with implant therapy late in the forecast period.  

Looking at the market from the standpoint of geography, the U.S. clearly dominates sales based on its expansive use of expensive implants.  However, its 74% share of global sales in 2019 is projected to decline slightly to 71% in 2024 as other nations expand their use of implants and as noninvasive technologies find increasing global acceptance.  Overall, the composite global market is projected to increase at a 12.7% real annual rate to $2.75 billion in 2024. 

For a detailed analysis of this market, become a Medtch Pro subscriber or purchase access to this single report.

Companies Covered

Abbott/St. Jude Medical

Adept Neuro SA

Aleva Neurotherapeutics

Bioness

Bionic Enterprises

Boston Scientific

Cala Health

Cerbomed

CerebralRx

Cervel Neurotech

Clinatec

CorTec/Wyss Center

CVRx

DARPA ElectRx

Deep Brain Innovations

Finetech Medical

Functional Neuromodulation

Hanger

LivaNova

Medtronic

MicroTransponder

Neuronetics

Neuronix

NeuroPace

NeuroSigma

Nexeon Medsystems

Ottobock

PINS Medical

SceneRay

Tal Medical

Table of Contents

Executive Summary 

Targeted Neurological Conditions 

Neurostimulation Technologies Targeting Neurological Disorders

Product Markets 

Supplier Shares

 

Summary Exhibit 1: Overview of Selected Neurological Conditions Currently Amenable to Neurostimulation Therapy 

Summary Exhibit 2: Current and Emerging Neurostimulation Technologies Targeting Neurological Conditions 

Summary Exhibit 3: Global Market for Neurostimulation Technologies Targeting Neurological Disorders by Major Type, Clinical Application and Major Geography, 2018 - 2024 

Summary Exhibit 4: Neurostimulation Technologies Targeting Neurological Conditions, Estimated Global Supplier Shares, 2018 

 

1. Targeted Neurological Conditions 

1.1 Refractory Epilepsy 

1.2 Chronic Depression 

1.3 Ischemic Stroke 

1.4 Neurodegenerative Disorders

1.4.1 Parkinson's Disease 

1.4.2 Essential Tremor 

1.4.3 Alzheimers 

1.5 Post-Traumatic Stress Disorder 

1.6 Migraine 

1.7 Cluster Headache 

 

Exhibit 1-1: Overview of Selected Neurological Conditions Currently Amenable to Neurostimulation Therapy 

Exhibit 1-2: Distribution of Depression by Geography, Age and Sex, 2015 

Exhibit 1-3: Current and Forecast Prevalence of Alzheimer's, 2015-2050 

 

2. Neurostimulation Technologies Targeting Neurological Conditions 

2.1 Drug Refractory Epilepsy

2.1.1 Bionic Enterprises 

2.1.2 Cerbomed/tVNS 

2.1.3 CerebralRX 

2.1.4 LivaNova 

2.1.5 NeuroPace 

2.1.6 NeuroSigma 

2.1.7 PINS Medical 

2.2 Major Depressive Disorder (Treatment Resistant Depression) 

2.2.1 BrainsWay 

2.2.2 Cerbomed/tVNS 

2.2.3 CerebralRx 

2.2.4 Endonovo Therapeutics/Cervel Neurotech 

2.2.5 LivaNova 

2.2.6 MagVenture 

2.2.7 Neuronetics 

2.2.8 Tal Medical 

2.3 Neurodegenerative Disorders

2.3.1 Aleva Neurotherapeutics 

2.3.2 Bioinduction 

2.3.3 Cala Health 

2.3.4 Functional Neuromodulation 

2.3.5 Neuronix 

2.4 Stroke, Spinal Cord Injury and Limb Loss 

2.4.1 Bioness

2.4.2 Finetech Medical 

2.4.3 Hanger 

2.4.4 MicroTransponder 

2.4.5 Ottobock 

 

Exhibit 2-1: Current and Emerging Neurostimulation Technologies Targeting Neurological Conditions 

 

3. Product Markets 

3.1 Parkinson's/Essential Tremor/Alzheimer's (Deep Brain Stimulation) 

3.1.1 Market by Major Geography 

3.1.2 Supplier Shares 

3.2 Drug-Refractory Epilepsy 

3.2.1 Market by Major Geography 

3.2.2 Supplier Shares 

3.3 Major Depressive Disorder 

3.3.1 Market by Major Geography 

3.3.2 Supplier Shares 

3.4 Post-Stroke Mobility 

3.4.1 Market by Major Geography 

3.4.2 Supplier Shares 

 

Exhibit 3-1: Global Market for Neurostimulation Technologies Targeting Neurological Disorders by Major Type, Clinical Application and Major Geography, 2018 - 2024 

Exhibit 3-2: Global Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders by Major Type and Major Geography, 2018 - 2024 

Exhibit 3-3: U.S. Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024 

Exhibit 3-4: Major Europe Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024 

Exhibit 3-5: Major Asia-Pacific Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024 

Exhibit 3-6: Rest-of-World Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024 

Exhibit 3-7: Neurostimulation Technologies Targeting Degenerative Neurological Disorders, Estimated Global Supplier Shares, 2018 

Exhibit 3-8: Global Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type and Major Geography, 2018 - 2024 

Exhibit 3-9: U.S. Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024 

Exhibit 3-10: Major Europe Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024

Exhibit 3-11: Major Asia-Pacific Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024 

Exhibit 3-12: Rest-of-World Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024

Exhibit 3-13: Estimated Global Supplier Shares of Technologies Targeting Drug-Refractory Epilepsy, 2018 

Exhibit 3-14: Global Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type and Major Geography, 2018 - 2024 

Exhibit 3-15: U.S. Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024 

Exhibit 3-16: Major Europe Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024 

Exhibit 3-17: Major Asia-Pacific Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024 

Exhibit 3-18: Rest-of-World Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024 

Exhibit 3-19: Estimated Global Supplier Shares of Technologies Targeting Major Depressive Disorder, 2018 

Exhibit 3-20: Global Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type and Major Geography, 2018 - 2024 

Exhibit 3-21: U.S. Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024 

Exhibit 3-22: Major Europe Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024 

Exhibit 3-23: Major Asia-Pacific Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024 

Exhibit 3-24: Rest-of-World Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024 

Exhibit 3-25: Estimated Global Supplier Shares of Technologies Targeting Post-Stroke Mobility, 2018